ScholarLens Back to search
2017•Evidence-Based PracticeRequires access

What is the rate of venous thromboembolism (VTE) in women taking combined oral contraceptives (COCs)?

Travis Lauder, Zachary LaMaster

Open publisher page 0 citations

Abstract

EVIDENCE-BASED ANSWER The rate of VTE in women taking COCs is approximately 0.06% per year. Third-generation and newer progestins (norgestimate, desogestrel, gestodene, drospirenone, and cyproterone acetate) are associated with greater risk of VTE (about 0.1% per year) (SOR: B, consistent findings from cohort studies).

About this research paper

What this paper is about

EVIDENCE-BASED ANSWER The rate of VTE in women taking COCs is approximately 0.06% per year. Third-generation and newer progestins (norgestimate, desogestrel, gestodene, drospirenone, and cyproterone acetate) are associated with greater risk of VTE (about 0.1% per year) (SOR: B, consistent findings from cohort studies).

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

EVIDENCE-BASED ANSWER The rate of VTE in women taking COCs is approximately 0.06% per year. Third-generation and newer progestins (norgestimate, desogestrel, gestodene, drospirenone, and cyproterone acetate) are associated with greater risk of VTE (about 0.1% per year) (SOR: B, consistent findings from cohort studies).

Key concepts: Gestodene, Drospirenone, Desogestrel, Medicine, Cyproterone acetate, Ethinylestradiol, Venous thromboembolism, Gynecology

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
What is the rate of venous thromboembolism (VTE) in women taking combined oral contraceptives (COCs)? — Research Paper | ScholarLens